Recent Advances on Anti – Angiogenesis Receptor Tyrosine Kinase Inhibitors in Cancer Therapy

Angiogenesis has always been the topic of major scientific interest in the field of malignant tumors. Nowadays, targeting angiogenesis has achieved success in various carcinomas by several mechanisms, including the use of
anti-angiogenic small molecule receptor tyrosine kinase inhibitors (TKIs). The development of TKIs targeting pro-angiogenic receptors, mainly vascular endothelial growth factor receptor (VEGFR) family, have significantly improved the outcome of certain types of cancers, like renal cell carcinoma, hepatocellular carcinoma, and colorectal carcinoma. However, the general response rate is not very satisfactory. The particular toxicity profile and resistance to anti-angiogenic targeted agents are unavoidable. To date, about 11 anti-angiogenic TKIs with different binding capacities to angiogenic receptor tyrosine kinase have been approved for the treatment of patients with advanced cancers. This review presents all approved antiangiogenic small molecule receptor TKIs so far with an emphasis on their indications and clinical efficacy.

• Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy

• ANGIOstream™ – VG

• ANGIOstream White Paper

• ANGIOstream™ – VR